m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04314)
Name
Cruentaren
Status
Preclinical
TTD Drug ID
D09IFW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Vacuolar-type proton ATPase catalytic A (v-ATPase-A)
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vacuolar-type proton ATPase catalytic A (v-ATPase-A) is a therapeutic target for Cruentaren. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Cruentaren through regulating the expression of Vacuolar-type proton ATPase catalytic A (v-ATPase-A). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vacuolar-type proton ATPase catalytic A (v-ATPase-A) is a therapeutic target for Cruentaren. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Cruentaren through regulating the expression of Vacuolar-type proton ATPase catalytic A (v-ATPase-A). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vacuolar-type proton ATPase catalytic A (v-ATPase-A) is a therapeutic target for Cruentaren. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cruentaren through regulating the expression of Vacuolar-type proton ATPase catalytic A (v-ATPase-A). [1], [2]
References
Ref 1 N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015 Feb 26;518(7540):560-4. doi: 10.1038/nature14234.
Ref 2 A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4150-3. doi: 10.1016/j.bmcl.2007.05.088. Epub 2007 Jun 3.